CL2020000360A1 - Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica. - Google Patents
Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica.Info
- Publication number
- CL2020000360A1 CL2020000360A1 CL2020000360A CL2020000360A CL2020000360A1 CL 2020000360 A1 CL2020000360 A1 CL 2020000360A1 CL 2020000360 A CL2020000360 A CL 2020000360A CL 2020000360 A CL2020000360 A CL 2020000360A CL 2020000360 A1 CL2020000360 A1 CL 2020000360A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- treatment
- compounds
- compositions
- indazole compounds
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 3
- 239000003623 enhancer Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009251 neurologic dysfunction Effects 0.000 title 1
- 208000015015 neurological dysfunction Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 229930195712 glutamate Natural products 0.000 abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPUESTOS DE INDAZOL QUE SON ÚTILES COMO POTENCIADORES ALOSTÉRICOS / MODULADORES ALOSTÉRICOS POSITIVOS DEL RECEPTOR METABOTRÓPICO DE GLUTAMATO SUBTIPO 4 (MGLUR4); MÉTODOS DE SÍNTESIS PARA FABRICA LOS COMPUESTOS; COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS; Y MÉTODOS PARA USAR LOS COMPUESTOS, POR EJEMPLO, EN EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS Y PSIQUIÁTRICOS U OTROS ESTADOS DE ENFERMEDAD ASOCIADOS CON LA DISFUNCIÓN DE GLUTAMATO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546290P | 2017-08-16 | 2017-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000360A1 true CL2020000360A1 (es) | 2020-07-31 |
Family
ID=63579734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000360A CL2020000360A1 (es) | 2017-08-16 | 2020-02-12 | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10508105B2 (es) |
| EP (1) | EP3668865A1 (es) |
| JP (1) | JP7253832B2 (es) |
| KR (1) | KR102687118B1 (es) |
| CN (1) | CN111225913B (es) |
| AU (1) | AU2018317403B2 (es) |
| BR (1) | BR112020003292A2 (es) |
| CA (1) | CA3072493A1 (es) |
| CL (1) | CL2020000360A1 (es) |
| CO (1) | CO2020002576A2 (es) |
| EA (1) | EA202090467A1 (es) |
| IL (1) | IL272575B2 (es) |
| PE (1) | PE20200756A1 (es) |
| SG (1) | SG11202001264UA (es) |
| UA (1) | UA128084C2 (es) |
| WO (1) | WO2019036534A1 (es) |
| ZA (1) | ZA202001321B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11242342B2 (en) | 2016-11-08 | 2022-02-08 | Vanderbilt University | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| IL272575B2 (en) | 2017-08-16 | 2023-09-01 | Univ Vanderbilt | Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunction |
| CA3145305A1 (en) | 2019-07-11 | 2021-01-14 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2024121367A1 (en) * | 2022-12-08 | 2024-06-13 | Boehringer Ingelheim International Gmbh | Novel substituted pyrazine-carboxamide-imidazopyridine derivatives |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2668811A1 (en) | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| WO2008061109A2 (en) * | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| EP2120932B1 (en) | 2006-12-20 | 2014-07-09 | Nerviano Medical Sciences S.r.l. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| WO2010088406A1 (en) | 2009-01-28 | 2010-08-05 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| SG177740A1 (en) | 2009-07-23 | 2012-02-28 | Univ Vanderbilt | Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators |
| EP2473055A4 (en) | 2009-09-04 | 2013-02-13 | Univ Vanderbilt | ALLOSTERIC MGLUR4 POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| KR20120088755A (ko) | 2009-10-22 | 2012-08-08 | 벤더르빌트 유니버시티 | Ｍｇｌｕｒ4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법 |
| CA2780128A1 (en) | 2009-11-06 | 2011-05-12 | P. Jeffrey Conn | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| KR20120120416A (ko) | 2010-02-11 | 2012-11-01 | 벤더르빌트 유니버시티 | Ｍｇｌｕｒ4 알로스테릭 강화제로서 벤즈이속사졸 및 아자벤즈이속사졸, 조성물, 및 신경 기능이상을 치료하는 방법 |
| EA201290774A1 (ru) | 2010-02-11 | 2013-03-29 | Вандербилт Юниверсити | Пиразолопиридиновые, пиразолопиразиновые, пиразолопиримидиновые, пиразолотиофеновые и пиразолотиазоловые соединения как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций |
| WO2011143466A1 (en) | 2010-05-12 | 2011-11-17 | Vanderbilt University | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| US9745271B2 (en) | 2014-03-20 | 2017-08-29 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| US9980945B2 (en) | 2015-01-13 | 2018-05-29 | Vanderbilt University | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016115272A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11242342B2 (en) | 2016-11-08 | 2022-02-08 | Vanderbilt University | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| IL272575B2 (en) | 2017-08-16 | 2023-09-01 | Univ Vanderbilt | Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunction |
-
2018
- 2018-08-16 IL IL272575A patent/IL272575B2/en unknown
- 2018-08-16 US US16/104,011 patent/US10508105B2/en active Active
- 2018-08-16 JP JP2020508581A patent/JP7253832B2/ja active Active
- 2018-08-16 PE PE2020000257A patent/PE20200756A1/es unknown
- 2018-08-16 SG SG11202001264UA patent/SG11202001264UA/en unknown
- 2018-08-16 AU AU2018317403A patent/AU2018317403B2/en active Active
- 2018-08-16 CA CA3072493A patent/CA3072493A1/en active Pending
- 2018-08-16 EP EP18769523.4A patent/EP3668865A1/en active Pending
- 2018-08-16 EA EA202090467A patent/EA202090467A1/ru unknown
- 2018-08-16 CN CN201880067616.7A patent/CN111225913B/zh active Active
- 2018-08-16 KR KR1020207007596A patent/KR102687118B1/ko active IP Right Grant
- 2018-08-16 WO PCT/US2018/046801 patent/WO2019036534A1/en unknown
- 2018-08-16 UA UAA202001405A patent/UA128084C2/uk unknown
- 2018-08-16 BR BR112020003292-1A patent/BR112020003292A2/pt unknown
- 2018-08-16 US US16/639,539 patent/US11427573B2/en active Active
-
2020
- 2020-02-12 CL CL2020000360A patent/CL2020000360A1/es unknown
- 2020-02-28 ZA ZA2020/01321A patent/ZA202001321B/en unknown
- 2020-03-04 CO CONC2020/0002576A patent/CO2020002576A2/es unknown
-
2022
- 2022-04-26 US US17/730,112 patent/US20220259190A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111225913A (zh) | 2020-06-02 |
| SG11202001264UA (en) | 2020-03-30 |
| US20220259190A1 (en) | 2022-08-18 |
| KR20200054204A (ko) | 2020-05-19 |
| US20200291019A1 (en) | 2020-09-17 |
| EA202090467A1 (ru) | 2020-06-18 |
| BR112020003292A2 (pt) | 2020-08-18 |
| US11427573B2 (en) | 2022-08-30 |
| JP2020531454A (ja) | 2020-11-05 |
| EP3668865A1 (en) | 2020-06-24 |
| ZA202001321B (en) | 2023-10-25 |
| IL272575B1 (en) | 2023-05-01 |
| CA3072493A1 (en) | 2019-02-21 |
| CO2020002576A2 (es) | 2020-04-01 |
| KR102687118B1 (ko) | 2024-07-19 |
| CN111225913B (zh) | 2024-05-31 |
| JP7253832B2 (ja) | 2023-04-07 |
| AU2018317403B2 (en) | 2023-09-21 |
| UA128084C2 (uk) | 2024-04-03 |
| IL272575A (en) | 2020-03-31 |
| US20190055225A1 (en) | 2019-02-21 |
| IL272575B2 (en) | 2023-09-01 |
| PE20200756A1 (es) | 2020-07-27 |
| US10508105B2 (en) | 2019-12-17 |
| AU2018317403A1 (en) | 2020-03-12 |
| WO2019036534A1 (en) | 2019-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000360A1 (es) | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica. | |
| CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| CL2019000827A1 (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador. | |
| CO2019007129A2 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
| CL2018002697A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos. | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
| NZ737399A (en) | Ccr2 modulators | |
| UY37098A (es) | Moduladores de ror-gamma | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| BR112012020273A2 (pt) | Compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica | |
| CL2019001129A1 (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y. | |
| CL2008002744A1 (es) | Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2. | |
| MX2018009952A (es) | Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1. | |
| BR112012020271A2 (pt) | Benzisoxazóis e azabenzisoxazóis como potencializadores alostéricos de mglur4 composições e métodos de tratamentos de disfunção neurológica | |
| GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| CO2020005417A2 (es) | Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd | |
| NZ739139A (en) | Dopamine d3 receptor antagonists having a bicyclo moiety | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| BR112018005589A2 (pt) | “composto, composição farmaceuticamente aceitável, e, uso de um composto” | |
| CL2016001739A1 (es) | Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2. | |
| BR112018016629A2 (pt) | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 | |
| CL2020002038A1 (es) | Oligonucleótidos para modular la expresión de tmem106b. |